



**CHIEF MEDICAL OFFICER
DEPARTMENT OF HEALTH
MINISTRY FOR HEALTH, THE ELDERLY AND COMMUNITY CARE**

DH CIRCULAR No.230/2011

DH.4735/2011

17th October 2011

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Rivaroxaban 10mg film coated tablets

Rivaroxaban 10mg film coated tablets has been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for introduction onto the Government Formulary List.

Rivaroxaban is a potent, selective, orally active direct inhibitor of the activated serine protease Factor X, which plays a central role in the blood coagulation. The recommended dose is 10mg taken orally once daily. The initial dose should be taken 6 to 10 hours after surgery, provided haemostasis has been established.

Consultant Orthopaedic Surgeons can prescribe Rivaroxaban for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.

Rivaroxaban 10mg film coated tablets is protocol-regulated with protocol number 290 (attached).

Rivaroxaban, 10mg film coated tablets has been procured through the Centralised Procurement and Supplies and are now available for use as per protocol.

Thank you

For your attention, please

Dr. Natasha Azzopardi Muscat
Chief Medical Officer

Rivaroxaban 10mg Tablets

Prescriber Criteria: Consultant Orthopaedic Surgeons

In-patients use:

Rivaroxaban is reserved for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery for a **maximum of 14 days**.